PT - JOURNAL ARTICLE AU - Marziano, Valentina AU - Guzzetta, Giorgio AU - Menegale, Francesco AU - Sacco, Chiara AU - Petrone, Daniele AU - Urdiales, Alberto Mateo AU - Del Manso, Martina AU - Bella, Antonino AU - Fabiani, Massimo AU - Vescio, Maria Fenicia AU - Riccardo, Flavia AU - Poletti, Piero AU - Manica, Mattia AU - Zardini, Agnese AU - d’Andrea, Valeria AU - Trentini, Filippo AU - Stefanelli, Paola AU - Rezza, Giovanni AU - Palamara, Anna Teresa AU - Brusaferro, Silvio AU - Ajelli, Marco AU - Pezzotti, Patrizio AU - Merler, Stefano TI - The decline of COVID-19 severity and lethality over two years of pandemic AID - 10.1101/2022.07.01.22277137 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.01.22277137 4099 - http://medrxiv.org/content/early/2022/07/02/2022.07.01.22277137.short 4100 - http://medrxiv.org/content/early/2022/07/02/2022.07.01.22277137.full AB - Undernotification of SARS-CoV-2 infections has been a major obstacle to the tracking of critical quantities such as infection attack rates and the probability of severe and lethal outcomes. We use a model of SARS-CoV-2 transmission and vaccination informed by epidemiological and genomic surveillance data to estimate the number of daily infections occurred in Italy in the first two years of pandemic. We estimate that the attack rate of ancestral lineages, Alpha, and Delta were in a similar range (10-17%, range of 95% CI: 7-23%), while that of Omicron until February 20, 2022, was remarkably higher (51%, 95%CI: 33-70%). The combined effect of vaccination, immunity from natural infection, change in variant features, and improved patient management massively reduced the probabilities of hospitalization, admission to intensive care, and death given infection, with 20 to 40-fold reductions during the period of dominance of Omicron compared to the initial acute phase.Competing Interest StatementM.A. has received research funding from Seqirus. The funding is not related to COVID-19. All other authors declare no competing interest.Funding StatementM.M., G.G., V.M., P.Po., F.T. and S.M. acknowledge funding from EU grant 874850 MOOD. The contents of this publication are the sole responsibility of the authors and don't necessarily reflect the views of the funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProcessed data and code will be made available in a public repository